Celldex Therapeutics Gears Up for Major Investor Conferences

Author: Dylan Bailey Updated: 03-04-2025 08:17 AM

Celldex Therapeutics Prepares for Key Investor Engagements

Celldex Therapeutics, Inc. (NASDAQ:CLDX) is excited to announce its participation in significant investor conferences that are on the horizon. These events represent an excellent opportunity for the company to connect with investors and share advancements in their innovative therapeutic solutions.

Fireside Chats to Highlight Advances

Management will engage in fireside chats, where they will outline the latest developments in their clinical research and therapeutic portfolio:

Upcoming Conference Dates

Celldex will be present at the TD Cowen 45th Annual Health Care Conference, scheduled for 1:50 p.m. ET on an upcoming Tuesday. Following that, they are set to participate in the Leerink Partners Global Healthcare Conference, which will take place at 1:00 p.m. ET the following week.

Live Presentation Access

Investors can look forward to live webcasts of the discussions. These will be accessible through the Events & Presentations page on the Celldex Therapeutics website. Those who are unable to attend the live sessions need not worry; replays will be available for a period of 90 days post-event, allowing ample time to catch up on critical insights.

About Celldex Therapeutics, Inc.

Celldex is at the forefront of biotechnology, particularly recognized for its pioneering work in the realm of mast cell biology. The company is dedicated to developing transformative therapeutics for patients suffering from a range of challenging health conditions. Their portfolio boasts antibody-based therapeutics designed to activate the human immune system and address critical pathways for treating severe inflammatory, allergic, autoimmune, and other life-altering diseases.

Commitment to Innovation

The ongoing dedication exhibited by Celldex Therapeutics towards innovation and patient care sets them apart in the biotechnology industry. Their research efforts aim to yield significant improvements in patient outcomes, ensuring that they remain an influential player in health care.

Company Contact Information

For any inquiries, interested parties can reach out to:

Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com

Patrick Till
Meru Advisors
(484) 788-8560
ptill@meruadvisors.com

Frequently Asked Questions

What is Celldex Therapeutics known for?

Celldex Therapeutics is known for its innovative approaches in biotechnology, particularly in developing therapeutics related to mast cell biology.

When will Celldex participate in the investor conferences?

Celldex will participate in the TD Cowen 45th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference on upcoming specified dates.

How can I access the live webcasts?

The live webcasts will be available on the Events & Presentations page of the Celldex website, allowing investors to tune in remotely.

Will there be replays available for the presentations?

Yes, replays of the presentations will be made available for 90 days after the live events, ensuring that all interested individuals can catch up on what was discussed.

Who can I contact for more information about Celldex?

Contact Sarah Cavanaugh or Patrick Till through the provided phone numbers or email addresses for any inquiries regarding Celldex Therapeutics.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.